New Research-Based Report in Biodex Software Promotes Safer Return-to-Play After ACL Reconstruction

SHIRLEY, N.Y., July 8, 2020 /PRNewswire-PRWeb/ — Following up the initial release of NEW Advantage BX software in January, Biodex Medical Systems, Inc. has enhanced the software with new reporting capabilities focused on getting injured athletes back in play safely. The first-ever Return-to-Play report displays isokinetic test results with clear pass/fail to aid in communication with physicians and athletes throughout the athlete’s recovery.

The new report is a response to the recent resurgence of isokinetic strength testing after ACL reconstruction. Research has shown strength symmetry and balanced hamstring to quadriceps ratios are major components of return-to-play criteria to reduce reinjury after ACL-R. Other criteria include functional test symmetry, agility testing, psychological readiness, and time.

Backed by current research and supported by a panel of experts, the report is designed to give patients and referring physicians the added confidence they are ready to return to play.

“The high failure of ACL reconstruction and the debate of when to return to play is a very active conversation throughout the world,” states Ed Behan, Sr. Vice President, Market Development at Biodex. “The new report is a first, and we’re grateful to have had so many key opinion leaders participating in its creation.”

Live chat with Biodex representatives during the NATA Athletic Trainers’ Virtual Convention, July 13-15, or visit https://www.biodex.com/s4bx for more information.

About Biodex Medical Systems, Inc.
Biodex Medical Systems, Inc. uses science and technology to drive treatment innovation across physical medicine, nuclear medicine and medical imaging categories. With a history of manufacturing and engineering excellence that spans more than 60 years, the Biodex mission is to provide innovative solutions and customer-driven support to medical facilities and wellness centers around the globe. For more information, visit http://www.biodex.com.

 

SOURCE Biodex Medical Systems, Inc.

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

13 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

16 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

16 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

16 hours ago